NCT03083613View on ClinicalTrials.gov

Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

September 1, 2017

Study Completion Date

December 1, 2018

Conditions
Gastric CancerGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Raltitrexed

Raltitrexed:3mg/m2,iv,d1, Every 3 weeks

DRUG

Paclitaxel

Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks

Trial Locations (1)

10000

Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Chinese Academy of Medical Sciences

OTHER

NCT03083613 - Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter